Reservoir Neuroscience, an Emeryville, CA-based developer of new therapies for age-related neurodegeneration, closed a $4M financing round.
The round was led by Kizoo Technology Capital, with additional participation from previous investors R42 Fund and Healthspan Ventures. In conjunction with the funding, Patrick Burgermeister, Partner of Kizoo Technology Capital, joined the board of Reservoir Neuroscience.
The company intends to use the funds to develop its novel class of drug compounds designed to restore health to the brain’s blood vessels to rejuvenate the aging brain.
Led by co-founders Aaron Friedman and Vlad Senatorov, Reservoir Neuroscience is an early-stage, venture-backed biotech advancing a novel therapy to reverse brain vascular pathology in aging and neurodegenerative diseases, where brain’s blood vessels become damaged and dysfunctional; causing inflammation that drives disease outcomes. This vascular pathology is a biomarker of neurodegeneration and defines patient segment yet has never been treated.
Commenting on the news, Aaron Friedman said: “By treating the underlying vascular problems that most patients inevitably develop through aging, we are addressing the single greatest risk factor for developing neurodegenerative disease. We believe this approach to rejuvenating the aging brain will be effective not only as a single therapy, but also has broader potential for brain health and systemic benefits in a wide variety of age-related diseases.”
FinSMEs
18/01/2024